Comparative Pharmacology
Head-to-head clinical analysis: DDAVP versus STIMATE NEEDS NO REFRIGERATION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DDAVP versus STIMATE NEEDS NO REFRIGERATION.
DDAVP vs STIMATE (NEEDS NO REFRIGERATION)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic analog of vasopressin; primarily activates V2 receptors in renal collecting ducts, increasing water reabsorption and concentrating urine.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.
Central diabetes insipidus: 0.1-0.4 mg orally every 12-24 hours or 0.5-1 mcg subcutaneously/intranasally every 12-24 hours. Nocturnal enuresis: 0.2-0.4 mg orally at bedtime. Hemophilia A/von Willebrand disease: 0.3 mcg/kg intravenous over 15-30 minutes or 300 mcg subcutaneously or 150 mcg intranasally (for >50 kg).
Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (intravenous); 3.4-4.4 hours (oral); clinical context: antidiuretic effect persists longer (6-20 hours) due to receptor binding.
Terminal elimination half-life is 2-4 hours (mean 3 hours), which supports a dosing interval of 2-4 hours in clinical use.
Primarily renal (unchanged drug); >90% eliminated by kidneys.
Renal excretion of intact drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog